on 02 Nov 2021
Last Applicant/ Owned by
LICHTENBERGSTRASSE 1
GARCHING
EU
85748
Serial Number
90447337 filed on 04th Jan 2021
Registration Number
6546779 registered on 02th Nov 2021
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography (PET) or single photon emission tomography (SPECT), target radionuclide and peptide receptor radionuclide therapy (PRRT); theranostics in the field of preci Read More
Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography (PET) or single photon emission tomography (SPECT), target radionuclide and peptide receptor radionuclide therapy (PRRT); theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumors; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET); radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; radiopharmaceuticals for use with high-sensitivity molecular imaging technologies such as PET (positron emission tomography) or SPECT (single photon emission tomography), for imaging organs and lesions and for early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumor diseases
Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; control, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators for radiopharmaceutical purposes
Conducting clinical trials in all stages and with various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)
Medical services, in particular services in the field of radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapy, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy (PRRT), personal nuclear medicine and precision oncology
No 90447337
No Service Mark
No 540.319US
No
No
No
No
No
No
No
No
26.01.13 -
Two circles
26.01.21 -
Circles that are totally or partially shaded
27.03.01 -
Geometric figures forming letters or numerals, including punctuation
Status Date | Action Taken |
---|---|
19th May 2022 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
02th Nov 2021 | REGISTERED-PRINCIPAL REGISTER |
17th Aug 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
17th Aug 2021 | PUBLISHED FOR OPPOSITION |
28th Jul 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
13th Jul 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
12th Jul 2021 | ASSIGNED TO EXAMINER |
03rd Apr 2021 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
02th Apr 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
28th Jan 2021 | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED |